Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):613–615. doi: 10.1128/aac.40.3.613

Potential use of WR6026 as prophylaxis against transfusion-transmitted American trypanosomiasis.

E Chiari 1, A B Oliveira 1, M A Prado 1, R J Alves 1, L M Galvão 1, F G Araujo 1
PMCID: PMC163167  PMID: 8851580

Abstract

Since transmission of Chagas' disease by the insect vector is under control in Brazil, transmission by blood transfusion is acquiring special relevance in areas where the disease is endemic and also in countries whose populations are free of infection but that are receiving immigrants from areas where the disease is endemic. Gentian violet, a phenylmethane dye, was the first agent used for the chemical prophylaxis of blood destined for transfusion. A concentration of 0.6 mmol of this dye per liter is effective at eliminating trypomastigotes from blood after 24 h of incubation at 4 degrees C. It is the only effective trypanosomicidal agent available. In the search of alternate compounds, we examined a number of synthetic compounds. They were screened for their activities against blood trypomastigotes of the Y, CL, and B229 strains of Trypanosoma cruzi by using two or more dilutions of each compound. We found that compound Q45, a 6-methoxy-8(diethylaminohexylamino)lepidine dihydrochloride, was highly effective at clearing parasites from infected blood. Doses of 65 and 130 micrograms of this compound eliminated trypomastigotes from blood experimentally contaminated with T. cruzi parasites. These results indicate that Q45 is remarkably active against circulating trypomastigotes. Further studies evaluating Q45 as a prophylactic agent for preventing the transmission of T. cruzi by blood transfusion are of interest.

Full Text

The Full Text of this article is available as a PDF (170.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araujo F. G., Huskinson-Mark J., Gutteridge W. E., Remington J. S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother. 1992 Feb;36(2):326–330. doi: 10.1128/aac.36.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Araujo F. G., Huskinson J., Remington J. S. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991 Feb;35(2):293–299. doi: 10.1128/aac.35.2.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BRENER Z., CHIARI E. VARIA C OES MORFOL'OGICAS OBSERVADAS EM DIFERENTES AMOSTRAS DE TRYPANOSOMA CRUZI. Rev Inst Med Trop Sao Paulo. 1963 Sep-Oct;5:220–224. [PubMed] [Google Scholar]
  4. Berman J. D., Lee L. S. Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. Am J Trop Med Hyg. 1983 Jul;32(4):753–759. doi: 10.4269/ajtmh.1983.32.753. [DOI] [PubMed] [Google Scholar]
  5. CAMARGO E. P. GROWTH AND DIFFERENTIATION IN TRYPANOSOMA CRUZI. I. ORIGIN OF METACYCLIC TRYPANOSOMES IN LIQUID MEDIA. Rev Inst Med Trop Sao Paulo. 1964 May-Jun;6:93–100. [PubMed] [Google Scholar]
  6. Camargo M. E. Fluorescent antibody test for the serodiagnosis of American trypanosomiasis. Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test. Rev Inst Med Trop Sao Paulo. 1966 Sep-Oct;8(5):227–235. [PubMed] [Google Scholar]
  7. Carneiro M., Romanha A. J., Chiari E. Biological characterization of Trypanosoma cruzi strains from different zymodemes and schizodemes. Mem Inst Oswaldo Cruz. 1991 Oct-Dec;86(4):387–393. doi: 10.1590/s0074-02761991000400002. [DOI] [PubMed] [Google Scholar]
  8. Chang H. R., Pechère J. C. Arteether, a qinghaosu derivative, in toxoplasmosis. Trans R Soc Trop Med Hyg. 1988;82(6):867–867. doi: 10.1016/0035-9203(88)90021-1. [DOI] [PubMed] [Google Scholar]
  9. Chiari E., de Oliveira A. B., Raslan D. S., Mesquita A. A., Tavares K. G. Screening in vitro of natural products against blood forms of Trypanosoma cruzi. Trans R Soc Trop Med Hyg. 1991 May-Jun;85(3):372–374. doi: 10.1016/0035-9203(91)90296-b. [DOI] [PubMed] [Google Scholar]
  10. Croft S. L., Walker J. J., Gutteridge W. E. Screening of drugs for rapid activity against Trypanosoma cruzi trypomastigotes in vitro. Trop Med Parasitol. 1988 Jun;39(2):145–148. [PubMed] [Google Scholar]
  11. Johnson J. L., Werbel L. M. Synthesis and antileishmanial activity of 6-methoxy-4-methyl-N-[6-(substituted-1-piperazinyl)hexyl]-8-quinolinamines and related compounds. J Med Chem. 1983 Feb;26(2):185–194. doi: 10.1021/jm00356a013. [DOI] [PubMed] [Google Scholar]
  12. Kerndt P. R., Waskin H. A., Kirchhoff L. V., Steurer F., Waterman S. H., Nelson J. M., Gellert G. A., Shulman I. A. Prevalence of antibody to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion. 1991 Nov-Dec;31(9):814–818. doi: 10.1046/j.1537-2995.1991.31992094668.x. [DOI] [PubMed] [Google Scholar]
  13. Kinnamon K. E., Steck E. A., Hanson W. L., Chapman W. L., Jr In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model. J Med Chem. 1977 Jun;20(6):741–744. doi: 10.1021/jm00216a001. [DOI] [PubMed] [Google Scholar]
  14. Kinnamon K. E., Steck E. A., Loizeaux P. S., Hanson W. L., Chapman W. L., Jr, Waits V. B. The antileishmanial activity of lepidines. Am J Trop Med Hyg. 1978 Jul;27(4):751–757. doi: 10.4269/ajtmh.1978.27.751. [DOI] [PubMed] [Google Scholar]
  15. Kirchhoff L. V., Gam A. A., Gilliam F. C. American trypanosomiasis (Chagas' disease) in Central American immigrants. Am J Med. 1987 May;82(5):915–920. doi: 10.1016/0002-9343(87)90152-5. [DOI] [PubMed] [Google Scholar]
  16. Klayman D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985 May 31;228(4703):1049–1055. doi: 10.1126/science.3887571. [DOI] [PubMed] [Google Scholar]
  17. NUSSENZWEIG V., BIANCALANA A., AMATO NETO V., SONNTAG R., DE FREITAS J. P., KLOETZEL J. Aço da violeta de genciana sôbre o T. cruzi in vitro: sua importância na esterilizaço do sangue destinado à transfusão. Rev Paul Med. 1953 Jan;42(1):57–58. [PubMed] [Google Scholar]
  18. Sherwood J. A., Gachihi G. S., Muigai R. K., Skillman D. R., Mugo M., Rashid J. R., Wasunna K. M., Were J. B., Kasili S. K., Mbugua J. M. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis. 1994 Dec;19(6):1034–1039. doi: 10.1093/clinids/19.6.1034. [DOI] [PubMed] [Google Scholar]
  19. Silva M. R., de Paiva e Rosália L. F., Jesuino S. A. Avaliaço do cetoconazol em camundongos inoculados com Paracoccidioides brasiliensis pela histopatologia de fígado e baço e pela intradermorreaço de paracoccidioidina. Rev Soc Bras Med Trop. 1994 Jan-Mar;27(1):11–14. doi: 10.1590/s0037-86821994000100003. [DOI] [PubMed] [Google Scholar]
  20. Skolnick A. Does influx from endemic areas mean more transfusion-associated Chagas' disease? JAMA. 1989 Sep 15;262(11):1433–1433. [PubMed] [Google Scholar]
  21. Theoharides A. D., Chung H., Velazquez H. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochem Pharmacol. 1985 Jan 15;34(2):181–188. doi: 10.1016/0006-2952(85)90122-4. [DOI] [PubMed] [Google Scholar]
  22. de Souza H. M. The present state of chemoprophylaxis in transfusional Chagas' disease. Rev Soc Bras Med Trop. 1989 Jan-Mar;22(1):1–3. doi: 10.1590/s0037-86821989000100001. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES